Leukadherin 1

Research use only, not for human use.

Leukadherin 1 (LA1) is a small molecule allosteric agonist of integrin CD11b/CD18 (CR3).

Leukadherin 1 (LA1) is a small molecule allosteric agonist of integrin CD11b/CD18 (CR3), increases CD11b/CD18-dependent cell adhesion to fibrinogen (EC50=4 uM); reduces IFN-I responses in WT but not CD11b-deficient mice, and protects lupus-prone MRL/Lpr mice from end-organ injury; reduces TLR-dependent proinflammatory signaling in leukocytes and suppresses IFN-I signaling via an AKT/FOXO3/IFN regulatory factor 3/7 pathway.

Leukadherin-1 is a specific agonist of the leukocyte surface integrin CD11b/CD18 (αMβ2; CR3; Mac-1). Leukadherin‐1 pretreatment reduces secretion of interferon (IFN)‐γ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)‐1β by monokine‐stimulated NK cells. Leukadherin‐1 pretreatment also reduces secretion of IL‐1β, IL‐6 and TNF by Toll‐like receptor (TLR)‐2 and TLR‐7/8‐stimulated monocytes.

Leukadherin-1 (1 mg/kg; i.p.; twice daily for 14 days) is beneficial in preventing hyperoxia-induced neonatal lung injury, an experimental model of bronchopulmonary dysplasia (BPD). Animal Model:Newborn Sprague Dawley rat pups Dosage:1 mg/kg Administration:I.p.; twice daily for 14 days Result:Beneficial on preventing the lung inflammatory response, improved alveolarization and vascular development, and reduced pulmonary vascular remodeling and PH in a hyperoxia-induced experimental model of BPD.

LA1

Immunology/Inflammation

Complement System

CD11b/CD18

Inflammation/Immunology

——

344897-95-6

421.49

C22H15NO4S2

>98% (HPLC)

DMSO: 15 mg/mL (35.59 mM); Water: <1 mg/mL; Ethanol: <1 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(O)C1=CC=C(C2=CC=C(/C=C(SC(N3CC4=CC=CC=C4)=S)/C3=O)O2)C=C1

4-[(5-[[4-Oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]benzoic acid

(-20℃)

With Ice Pack

≥ 2 years